Diagnostic Challenges due to a Germline Missense MSH2 Variant in a Patient With Immunotherapy‐Responsive Locally Advanced Rectal Adenocarcinoma
2024

Diagnostic Challenges of a MSH2 Variant in Rectal Cancer

Sample size: 1 publication Evidence: moderate

Author Information

Author(s): Evaristo Gertruda, Harmath Carla, Segal Jeremy P., Shergill Ardaman, Setia Namrata

Primary Institution: The University of Chicago

Hypothesis

Can a germline MSH2 variant affect the response to immunotherapy in rectal adenocarcinoma?

Conclusion

The study highlights the importance of an integrative approach to assess MMR status for immunotherapy candidacy, even when traditional tests show no deficiency.

Supporting Evidence

  • The patient had a germline MSH2 variant classified as a variant of undetermined significance.
  • Immunotherapy led to successful disease control over a 33-month follow-up.
  • NGS-based identification of microsatellite instability was crucial for treatment decision.

Takeaway

A young woman with rectal cancer had a genetic variant that made her respond well to immunotherapy, even though tests didn't show typical signs of cancer weakness.

Methodology

The study involved genetic sequencing and immunohistochemistry to assess MMR status and tumor characteristics.

Limitations

The absence of functional studies confirming the deleterious effect of the MSH2 variant is a limitation.

Participant Demographics

A 35-year-old female patient with a family history of multiple cancers.

Digital Object Identifier (DOI)

10.1002/cnr2.70037

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication